You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company will use the funds to expand its clinical genomic testing efforts into additional towns and cities in India, and accelerate its drug discovery programs.
After around six months, Genetic Signatures anticipates merging its SARS-CoV-2 test with a respiratory disease testing kit.
Myriad has partnered with Japanese firm SRL, a subsidiary of Miraca Group, to commercialize its BRACAnalysis Diagnostic System in Japan.
The company said the kit can provide results within 90 minutes, with sensitivity and specificity of detection reaching the level of traditional PCR methods.
Droplet digital PCR tests for SARS-CoV-2 can potentially detect the very low viral loads seen in asymptomatic and convalescent cases.
In addition, Biolidics entered a distribution agreement with Clearbridge Medical Group to distribute tests in multiple Asian countries and Australia.
Sysmex anticipates delivering the kit to Japanese medical institutions this month for diagnosis of the SARS-CoV-2 infection.
The BGI Real-Time Fluorescent RT-PCR Kit for detecting SARS-2019-nCoV runs in approximately three hours and can be manufactured in large volumes, the firm has said.
The kit, which is CE marked, is designed to detect the virus' ORF1ab, N, and E genes, and can process 96 samples within two hours.
The point-of-care test is designed for the qualitative presumptive detection of specific IgM and IgG antibodies to SARS-CoV-2 in a fingerstick blood sample.